In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacific Biosciences of California Inc.

www.pacificbiosciences.com

Latest From Pacific Biosciences of California Inc.

Decade In Review: Biopharma's Shifting Legal Landscape

Emergence of the inter partes review process dramatically changed the patent dispute arena.  The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.

Legal Issues Biosimilars

Illumina Pays Pacific Biosciences $98M To Terminate $1.2Bn Merger Deal

Illumina had planned to acquire Pacific Biosciences to add the company's “long-read” gene sequencing systems to Illumina's own range of "short-read" technologies. However, the UK’s Competition and Markets Authority and the US Federal Trade Commission concluded that the deal would significantly reduce competition in the DNA sequencing market.

Deals M & A

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Commercial Innovation

Illumina CSO Bentley Paints A Vision For The Future Of Precision Medicine

Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.

C-Suite Speaks Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nanofluidics Inc.
  • Pacific Biosciences Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pacific Biosciences of California Inc.
  • Senior Management
  • Michael W Hunkapiller, Pres. & CEO
    Susan K Barnes, EVP, CFO
    Jonas Korlach, PhD, CSO
    Kathy Ordonez, EVP, Chief Commercial Officer
  • Contact Info
  • Pacific Biosciences of California Inc.
    Phone: (650) 521-8000
    1305 O'Brien Dr.
    Menlo Park, CA 94025
    USA
UsernamePublicRestriction

Register